Evidence map›Paper›PMID 32561640›Full record

ArticleThe Journal of biological chemistry2020

The guanine nucleotide exchange factor VAV3 participates in ERBB4-mediated cancer cell migration.

Veera K Ojala, Anna M Knittle, Peppi Kirjalainen, Johannes A M Merilahti, Maarit Kortesoja, Denis Tvorogov, Katri Vaparanta, Shujun Lin, Jürgen Kast, Arto T Pulliainen and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Subtype-Specific mInternational journal of molecular sciences · 2026
    Article
  3. Article
  4. Prognostic Significance ofBiomedicines · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Veera K OjalaInstitute of Biomedicine and Medicity Research Laboratories, University of Turku, Turku, Finland.ORCID 0000-0001-5204-8899
Anna M KnittleInstitute of Biomedicine and Medicity Research Laboratories, University of Turku, Turku, Finland.
Peppi KirjalainenInstitute of Biomedicine and Medicity Research Laboratories, University of Turku, Turku, Finland.
Johannes A M MerilahtiInstitute of Biomedicine and Medicity Research Laboratories, University of Turku, Turku, Finland.ORCID 0000-0002-9113-5175
Maarit KortesojaInstitute of Biomedicine and Medicity Research Laboratories, University of Turku, Turku, Finland.
Denis TvorogovInstitute of Biomedicine and Medicity Research Laboratories, University of Turku, Turku, Finland.ORCID 0000-0002-2009-1347
Katri VaparantaInstitute of Biomedicine and Medicity Research Laboratories, University of Turku, Turku, Finland.ORCID 0000-0002-3574-4427
Shujun LinBiomedical Research Centre, Department of Chemistry, and Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.
Jürgen KastBiomedical Research Centre, Department of Chemistry, and Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.
Arto T PulliainenInstitute of Biomedicine and Medicity Research Laboratories, University of Turku, Turku, Finland.ORCID 0000-0002-9361-8963
Kari J KurppaInstitute of Biomedicine and Medicity Research Laboratories, University of Turku, Turku, Finland.
Klaus EleniusInstitute of Biomedicine and Medicity Research Laboratories, University of Turku, Turku, Finland klaus.elenius@utu.fi.ORCID 0000-0001-5700-0827
Åbo Akademi University · FIUniversity of Turku · FIUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ERBB4 is a member of the epidermal growth factor receptor (EGFR)/ERBB subfamily of receptor tyrosine kinases that regulates cellular processes including proliferation, migration, and survival. ERBB4 signaling is involved in embryogenesis and homeostasis of healthy adult tissues, but also in human pathologies such as cancer, neurological disorders, and cardiovascular diseases. Here, an MS-based analysis revealed the Vav guanine nucleotide exchange factor 3 (VAV3), an activator of Rho family GTPases, as a critical ERBB4-interacting protein in breast cancer cells. We confirmed the ERBB4-VAV3 interaction by targeted MS and coimmunoprecipitation experiments and further defined it by demonstrating that kinase activity and Tyr-1022 and Tyr-1162 of ERBB4, as well as the intact phosphotyrosine-interacting SH2 domain of VAV3, are necessary for this interaction. We found that ERBB4 stimulates tyrosine phosphorylation of the VAV3 activation domain, known to be required for guanine nucleotide exchange factor (GEF) activity of VAV proteins. In addition to VAV3, the other members of the VAV family, VAV1 and VAV2, also coprecipitated with ERBB4. Analyses of the effects of overexpression of dominant-negative VAV3 constructs or shRNA-mediated down-regulation of VAV3 expression in breast cancer cells indicated that active VAV3 is involved in ERBB4-stimulated cell migration. These results define the VAV GEFs as effectors of ERBB4 activity in a signaling pathway relevant for cancer cell migration.

Indexed as

Cell MovementAnimalsBreast NeoplasmsFemaleHEK293 CellsHumansMCF-7 CellsMiceNIH 3T3 CellsProtein Interaction MapsProto-Oncogene Proteins c-vavReceptor, ErbB-4ERBB4 protein, humanProto-Oncogene Proteins c-vavReceptor, ErbB-4VAV3 protein, humanbreast cancercancercell migrationERBB4guanine nucleotide exchange factor (GEF)HER4phosphotyrosine signalingprotein-protein interactionreceptor tyrosine kinaseVav guanine nucleotide exchange factor 3 (VAV3)

Identifiers

PMID32561640
PMCPMC7450113
OpenAlexW3036364287

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.